Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Antidepressants are selective serotonin neuronal reuptake inhibitors: 40-year history

https://doi.org/10.14412/2074-2711-2015-1-66-74

Full Text:

Abstract

The paper presents historical prerequisites for designing antidepressants from a group of selective serotonin neuronal reuptake inhibitors (SSRIs): to determine a lower serotonin concentration in the different tissues of depressed patients; to establish a higher serotonin concentration in the treatment of depressed patients with tricyclic antidepressants, and to formulate the serotonergic theory of depression. It also provides a consecutive account of the history of clinical introduction of individual SSRI representatives, such as fluoxetine, zimelidine, fluvoxamine, indalpine, citalopram, sertraline, paroxetine, and escitalopram. There are data from the history of studying the mechanism of SSRI action: from the theory of the importance of an increase in the concentration of serotonin in the synaptic cleft to the current understanding of complex successive intracellular rearrangements at the level of the postsynaptic neuron. The history of studying the efficacy of SSRIs in treating depression is considered in detail. Emphasis is laid on the reasons for a paradoxical difference in the evaluations of the efficiency of therapy with SSRIs versus other groups of antidepressants at different developmental stages of psychopharmacology. The role of marketing technologies in disseminating the data on the efficacy of this or that group of antidepressants is described. The practical significance of differences in individual SSRI representatives (the potency of serotonin uptake inhibition; the degree of selectivity and activity against the serotonergic system; the likelihood of an unfavorable pharmacokinetic interaction with other drugs; the half-life of elimination; the quickness of achieving a therapeutic dose) is analyzed. Whether it is possible and reasonable to differentially choose different SSRI representatives in the treatment of depressions at the present stage is discussed. The authors state their belief that researches should be continued to specify the place of SSRIs among other groups of current antidepressants for the treatment of depressions. 

About the Author

D. S. Danilov
S.S. Korsakov Clinic of Psychiatry and «Mental Health» Research, Education and Clinical Center, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia 11, Rossolimo St., Build. 9, Moscow 119021
Russian Federation


References

1. Дробижев МЮ. Селективные ингибиторы обратного захвата серотонина и норадреналина: возможно ли сочетание эффективности и безопасности? Психиатрия и психофармакотерапия. 2004;6(5):248–50. [Drobizhev MYu. Selective inhibitors of reuptake of serotonin and noradrenaline (norepinephrine): possible combination of efficacy and safety. Psikhiatriya i psikhofarmakoterapiya. 2004;6(5):248–50. (In Russ.)].

2. Scull AT, editor. Cultural sociology of mental illness: An A-to-Z Guide. Thousand Oaks: SAGE Publications; 2014. 1176 p.

3. Lapin IP, Oxenkrug GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet. 1969 Jan 18;1(7586):132–6.

4. Wong DT, Horng JS, Bymaster FP, et al. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-Nmethyl-3-phenylpropylamine. Life Sci. 1974 Aug 1;15(3):471–9.

5. Fuller RW, Perry KW, Molloy BB. Effect of an uptake inhibitor on serotonin metabolism in rat brain: studies with 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine (Lilly 110140). Life Sci. 1974 Sep 15;15(6):1161–71.

6. Ross SB, Ogren SO, Renyi AL. (Z)-dimethylamino-1-(4-bromophenyl)-1-(3-pyridyl) propene (h 102/09), a new selective inhibitor of the neuronal 5-hydroxytryptamine uptake. Acta Pharmacol Toxicol (Copenh). 1976 Aug;39(2):152–66.

7. Carlsson A, Wong DT. A note on the discovery of selective serotonin reuptake inhibitors. Life Sci. 1997;61(12):1203.

8. Bengtsson BO, Wiholm BE, Myrhed M, et al. Adverse experiences during treatment with zimeldine on special licence in Sweden. Int Clin Psychopharmacol. 1994 Spring;9(1):55–61.

9. Meltzer HY, Young M, Metz J, et al. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm. 1979;45(2):165–75.

10. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl). 1986;90(1):131–8.

11. Danish Universities Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord. 1990 Apr;18(4):289–99.

12. Lundbeck AS. Annual report. 2000: 10–11, 13, 28, 30–32.

13. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998 Dec;51(3):215–35.

14. Балдессарини Р. Медикаментозное лечение депрессии и тревожных расстройств. В кн.: Клиническая фармакология по Гудману и Гилману. Под ред. А. Г. Гилмана. Москва: Практика; 2006. С. 350–82. [Baldessarini R. Drug treatment of depression and anxiety disorders. In: Klinicheskaya farmakologiya po Gudmanu i Gilmanu [Clinical pharmacology by Goodman and Gilman]. Gilman AG, editor. Moscow: Praktika; 2006. P. 350–82.]

15. Lee BH, Kim YK. The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig. 2010 Dec;7(4):231–5. doi: 10.4306/pi.2010.7.4.231. Epub 2010 Nov 23.

16. Siever LJ, Davis KL. Overview: toward dysregulation hypothesis of depression. Am J Psychiatry. 1985 Sep;142(9):1017–31.

17. Шацберг АФ, Коул ДО, ДеБаттиста Ч. Руководство по клинической психофармакологии. Под ред. А.Б. Смулевича, С.В. Иванова. Москва: МЕДпресс-информ; 2013. 608 с. [Shatsberg AF, Koul DO, DeBattista Ch. Rukovodstvo po klinicheskoi psikhofarmakologii [Manual of clinical psychopharmacology]. Smulevich AB, Ivanov SV, editors. Moscow: MЕDpress-inform; 203. 608 p.].

18. Попов ЮВ, Вид ВД. Современная клиническая психиатрия. Москва: Экспертное бюро-М; 1997. 496 с. [Popov YuV, Vid VD. Sovremennaya klinicheskaya psikhiatriya [Modern clinical psychiatry]. Moscow: Ekspertnoe byuro-M; 1997. 496 p.].

19. Яничак ФДж, Дэвис ДжМ, Прескорн ШХ и др. Принципы и практика психофармакотерапии. Киев: Ника-Центр; 1999. 728 с. [Yanichak FJ, Devis DJ, Preskorn SH, et al. Printsipy i praktika psikhofarmakoterapii [Principles and practice of psychopharmacotherapy]. Kiev: Nika-Tsentr; 1999. 728 p.].

20. Арана Дж, Розенбаум Дж. Фармакотерапия психических расстройств. Под ред. С.Н. Мосолова. Москва: БИНОМ; 2004. 416 с. [Arana J, Rozenbaum J. Farmakoterapiya psikhicheskikh rasstroistv [Pharmacotherapy of mental disorders]. Mosolov SN, editor. Moscow: BINOM; 2004. 416 p.].

21. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000 Apr;58(1):19–36.

22. Ansseau M, Papart P, Troisfontaines B, et al. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology (Berl). 1994 Feb;114(1):131–7.

23. Guelfi JD, Ansseau M, Corruble E, et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol. 1998 May;13(3):121–8.

24. Lee MS, Ham BJ, Kee BS, et al. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. Curr Med Res Opin. 2005 Sep;21(9):1369–75.

25. Clerc G. Milnacipran/Fluvoxamine Study Group. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol. 2001 May;16(3):145–51.

26. Morishita S, Arita S. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age. Hum Psychopharmacol. 2004 Aug;19(6):405–8.

27. Eckert L, Lancon C. Duloxetine compared with fluoxetine and venlafaxine: use of metaregression analysis for indirect comparisons. BMC Psychiatry. 2006 Jul 24;6:30.

28. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multipletreatments meta-analysis. Lancet. 2009 Feb 28;373(9665):746–58. doi: 10.1016/S0140-6736(09)60046-5.

29. Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Br J Psychiatry. 2000 Oct;177:292–302.

30. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008 Jan 17;358(3):252–60. doi: 10.1056/NEJMsa065779.

31. Медведев ВЭ. Сигма-рецепторы: роль в лечении аффективных расстройств. Неврология, нейропсихиатрия, психосоматика. 2012;(2):105–7. [Medvedev VE. Sigma receptors: their role in the treatment of affective disorders. Nevrologija, nejropsihiatrija, psihosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;(2):105–7. (In Russ.)]. doi: http://dx.doi.org/10.14412/2074-27112012-395


For citation:


Danilov D.S. Antidepressants are selective serotonin neuronal reuptake inhibitors: 40-year history. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(1):66-74. (In Russ.) https://doi.org/10.14412/2074-2711-2015-1-66-74

Views: 1949


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)